FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310398840> ?p ?o ?g. }

• W4310398840 abstract "Summary The rapid rise in the use of immune checkpoint inhibitors as systemic cancer therapy has seen the emergence of immunotherapy-induced diabetes, a severe irreversible immunotherapy-related adverse event. Affected patients typically present with diabetic ketoacidosis (DKA) and low C-peptide consistent with insulin deficiency secondary to autoimmune β-cell destruction. We present the unusual case of a 61-year-old female with metastatic ampullary duodenal adenocarcinoma with primary tumour adjacent to the pancreatic head. She was commenced on immunotherapy after conventional systemic chemotherapy. Acute-onset hyperglycaemia was detected after 7 weeks on weekly blood glucose monitoring, with no glucocorticoid use or prior history of diabetes. On presentation, there was no evidence of DKA, and her glycated haemoglobin level was within the normal non-diabetic range at 5.3%, reflecting the acuity of her presentation. Initial serum C-peptide was preserved; however, it became undetectable a few weeks later, confirming insulin deficiency. We describe a case of atypical presentation of immunotherapy-induced diabetes, review the existing literature on this emerging clinical entity and discuss the differential diagnosis for new-onset diabetes mellitus in patients with metastatic cancer. Learning points Regular proactive glycaemic monitoring in patients receiving immunotherapy, particularly antibodies against programmed death ligand 1 and PD1, can facilitate very early detection of immunotherapy-induced diabetes, prompting insulin commencement and avoiding life-threatening presentations of diabetic ketoacidosis. Glycated haemoglobin can be within the normal range in patients diagnosed acutely with immunotherapy-induced diabetes. Serum C-peptide can be preserved initially in patients diagnosed with immunotherapy-induced diabetes but is likely to become undetectable during their illness. New-onset diabetes in patients with metastatic cancer carries a broad differential diagnosis." @default.
• W4310398840 created "2022-12-10" @default.
• W4310398840 creator A5035719297 @default.
• W4310398840 creator A5044660371 @default.
• W4310398840 creator A5091080617 @default.
• W4310398840 date "2022-11-01" @default.
• W4310398840 modified "2023-09-30" @default.
• W4310398840 title "Acute presentation of immunotherapy-related diabetes mellitus without ketoacidosis, low C-peptide or elevated HbA1c" @default.
• W4310398840 cites W2066671159 @default.
• W4310398840 cites W2531851839 @default.
• W4310398840 cites W2808896902 @default.
• W4310398840 cites W2811140989 @default.
• W4310398840 cites W2891536507 @default.
• W4310398840 cites W2954626501 @default.
• W4310398840 cites W3119919857 @default.
• W4310398840 cites W3185041154 @default.
• W4310398840 doi "https://doi.org/10.1530/edm-22-0291" @default.
• W4310398840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36448841" @default.
• W4310398840 hasPublicationYear "2022" @default.
• W4310398840 type Work @default.
• W4310398840 citedByCount "1" @default.
• W4310398840 countsByYear W43103988402023 @default.
• W4310398840 crossrefType "journal-article" @default.
• W4310398840 hasAuthorship W4310398840A5035719297 @default.
• W4310398840 hasAuthorship W4310398840A5044660371 @default.
• W4310398840 hasAuthorship W4310398840A5091080617 @default.
• W4310398840 hasBestOaLocation W43103988401 @default.
• W4310398840 hasConcept C121608353 @default.
• W4310398840 hasConcept C126322002 @default.
• W4310398840 hasConcept C134018914 @default.
• W4310398840 hasConcept C2775849729 @default.
• W4310398840 hasConcept C2777701055 @default.
• W4310398840 hasConcept C2779306644 @default.
• W4310398840 hasConcept C2781232474 @default.
• W4310398840 hasConcept C2781283889 @default.
• W4310398840 hasConcept C555293320 @default.
• W4310398840 hasConcept C71924100 @default.
• W4310398840 hasConceptScore W4310398840C121608353 @default.
• W4310398840 hasConceptScore W4310398840C126322002 @default.
• W4310398840 hasConceptScore W4310398840C134018914 @default.
• W4310398840 hasConceptScore W4310398840C2775849729 @default.
• W4310398840 hasConceptScore W4310398840C2777701055 @default.
• W4310398840 hasConceptScore W4310398840C2779306644 @default.
• W4310398840 hasConceptScore W4310398840C2781232474 @default.
• W4310398840 hasConceptScore W4310398840C2781283889 @default.
• W4310398840 hasConceptScore W4310398840C555293320 @default.
• W4310398840 hasConceptScore W4310398840C71924100 @default.
• W4310398840 hasLocation W43103988401 @default.
• W4310398840 hasLocation W43103988402 @default.
• W4310398840 hasLocation W43103988403 @default.
• W4310398840 hasOpenAccess W4310398840 @default.
• W4310398840 hasPrimaryLocation W43103988401 @default.
• W4310398840 hasRelatedWork W2016685050 @default.
• W4310398840 hasRelatedWork W2017127800 @default.
• W4310398840 hasRelatedWork W2084410721 @default.
• W4310398840 hasRelatedWork W2092579885 @default.
• W4310398840 hasRelatedWork W2385384335 @default.
• W4310398840 hasRelatedWork W2411811454 @default.
• W4310398840 hasRelatedWork W2597203416 @default.
• W4310398840 hasRelatedWork W2611456965 @default.
• W4310398840 hasRelatedWork W4235202509 @default.
• W4310398840 hasRelatedWork W4241184119 @default.
• W4310398840 hasVolume "2022" @default.
• W4310398840 isParatext "false" @default.
• W4310398840 isRetracted "false" @default.
• W4310398840 workType "article" @default.